The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.

Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the patient will experience a recurrence years after their initial diagnosis. Now, ...